The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were…

Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne to advance its CAR-T programs utilising…

Prescient Therapeutics Ltd (ASX:PTX) has signed an agreement related to advancing a new research program with world-renowned Peter MacCallum Cancer Centre to advance its next-generation CAR-T…

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs. CAR-T is a type…

Biotech company Prescient Therapeutics (ASX:PTX) had an important announcement for the market this morning, after strengthening its ties in research and development with the world-renowned Peter MacCallum…

Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre to advance work on its revolutionary OmniCAR platform. Under the…

Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid…

Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat bone marrow is progressing to a higher dose. Three of…

The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion by 2030, according to new research. Figures published by research…

CAR-T Cell Immunotherapy Market Segmentation by Key Companies, Key Regions, Types and Application segmentation – History and Global Forecast 2021-2027 A comprehensive study of the…